 Toshimasa Clark
Concepts (136)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Image Interpretation, Computer-Assisted | 4 | 2017 | 264 | 1.340 |
Why?
| | Radiology Information Systems | 3 | 2019 | 30 | 1.160 |
Why?
| | Contrast Media | 4 | 2019 | 469 | 1.090 |
Why?
| | Thyroid Nodule | 2 | 2019 | 55 | 1.070 |
Why?
| | Magnetic Resonance Angiography | 2 | 2019 | 239 | 0.960 |
Why?
| | Radiology | 3 | 2017 | 177 | 0.960 |
Why?
| | Algorithms | 5 | 2019 | 1701 | 0.920 |
Why?
| | Decision Support Systems, Clinical | 2 | 2017 | 238 | 0.790 |
Why?
| | Incidental Findings | 3 | 2019 | 79 | 0.750 |
Why?
| | Practice Guidelines as Topic | 4 | 2019 | 1541 | 0.720 |
Why?
| | Tomography, X-Ray Computed | 3 | 2016 | 2679 | 0.640 |
Why?
| | Adrenocortical Adenoma | 1 | 2019 | 2 | 0.610 |
Why?
| | Meglumine | 1 | 2019 | 18 | 0.610 |
Why?
| | Multidetector Computed Tomography | 1 | 2019 | 40 | 0.590 |
Why?
| | Organometallic Compounds | 1 | 2019 | 110 | 0.570 |
Why?
| | Image Enhancement | 1 | 2019 | 189 | 0.560 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2019 | 88 | 0.560 |
Why?
| | Sensitivity and Specificity | 6 | 2019 | 1941 | 0.530 |
Why?
| | Radiation Protection | 1 | 2017 | 39 | 0.520 |
Why?
| | Programming Languages | 1 | 2016 | 26 | 0.510 |
Why?
| | Radiography, Interventional | 1 | 2017 | 115 | 0.500 |
Why?
| | Data Mining | 1 | 2017 | 116 | 0.490 |
Why?
| | Radiologists | 1 | 2016 | 49 | 0.490 |
Why?
| | Gadolinium | 1 | 2016 | 81 | 0.490 |
Why?
| | Computed Tomography Angiography | 1 | 2017 | 130 | 0.490 |
Why?
| | Ultrasonography | 2 | 2019 | 762 | 0.490 |
Why?
| | Decision Making, Computer-Assisted | 1 | 2015 | 17 | 0.480 |
Why?
| | Radiation Dosage | 1 | 2017 | 188 | 0.480 |
Why?
| | Models, Cardiovascular | 1 | 2016 | 195 | 0.460 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 109 | 0.450 |
Why?
| | Blood Flow Velocity | 1 | 2016 | 413 | 0.450 |
Why?
| | Guideline Adherence | 2 | 2016 | 551 | 0.440 |
Why?
| | Arteries | 1 | 2016 | 261 | 0.440 |
Why?
| | Computer Simulation | 2 | 2016 | 987 | 0.440 |
Why?
| | Mobile Applications | 1 | 2016 | 177 | 0.410 |
Why?
| | Medical Records Systems, Computerized | 1 | 2014 | 95 | 0.410 |
Why?
| | User-Computer Interface | 1 | 2014 | 162 | 0.400 |
Why?
| | Thyroid Neoplasms | 1 | 2016 | 324 | 0.370 |
Why?
| | Documentation | 1 | 2014 | 199 | 0.370 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2016 | 748 | 0.370 |
Why?
| | Quality Improvement | 2 | 2017 | 1180 | 0.360 |
Why?
| | Splenic Diseases | 1 | 2011 | 9 | 0.350 |
Why?
| | Neoplasms | 2 | 2016 | 2691 | 0.350 |
Why?
| | Early Detection of Cancer | 1 | 2015 | 432 | 0.340 |
Why?
| | Reproducibility of Results | 4 | 2019 | 3287 | 0.320 |
Why?
| | Abdominal Injuries | 1 | 2011 | 120 | 0.310 |
Why?
| | Prostatic Neoplasms | 1 | 2017 | 1049 | 0.310 |
Why?
| | Software | 1 | 2014 | 664 | 0.300 |
Why?
| | Spleen | 1 | 2011 | 521 | 0.290 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1299 | 0.280 |
Why?
| | Thyroid Gland | 2 | 2019 | 91 | 0.270 |
Why?
| | Emergency Service, Hospital | 1 | 2017 | 2093 | 0.240 |
Why?
| | Software Validation | 2 | 2016 | 9 | 0.240 |
Why?
| | Magnetic Resonance Imaging | 1 | 2017 | 3607 | 0.230 |
Why?
| | Middle Aged | 9 | 2024 | 33441 | 0.210 |
Why?
| | Humans | 18 | 2024 | 137601 | 0.190 |
Why?
| | Pancreatectomy | 1 | 2024 | 238 | 0.180 |
Why?
| | Neoadjuvant Therapy | 1 | 2024 | 407 | 0.180 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2024 | 265 | 0.170 |
Why?
| | Liver Neoplasms | 2 | 2019 | 762 | 0.170 |
Why?
| | Male | 10 | 2024 | 67690 | 0.170 |
Why?
| | Body Composition | 1 | 2024 | 695 | 0.160 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2020 | 60 | 0.150 |
Why?
| | Adrenocortical Carcinoma | 1 | 2020 | 63 | 0.150 |
Why?
| | Injections, Intravenous | 1 | 2019 | 197 | 0.150 |
Why?
| | Retrospective Studies | 5 | 2024 | 15720 | 0.150 |
Why?
| | Risk Assessment | 2 | 2019 | 3438 | 0.150 |
Why?
| | Female | 11 | 2024 | 73359 | 0.150 |
Why?
| | Artifacts | 1 | 2019 | 129 | 0.150 |
Why?
| | Pancreatic Pseudocyst | 1 | 2018 | 17 | 0.140 |
Why?
| | Aneurysm, False | 1 | 2018 | 45 | 0.140 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2020 | 253 | 0.140 |
Why?
| | Famous Persons | 1 | 2017 | 7 | 0.130 |
Why?
| | Drainage | 1 | 2018 | 173 | 0.130 |
Why?
| | Pancreatic Neoplasms | 1 | 2024 | 853 | 0.120 |
Why?
| | Observer Variation | 1 | 2017 | 349 | 0.120 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2019 | 359 | 0.120 |
Why?
| | Neoplasm Grading | 1 | 2017 | 304 | 0.120 |
Why?
| | Efficiency, Organizational | 1 | 2017 | 139 | 0.120 |
Why?
| | Prospective Studies | 2 | 2019 | 7580 | 0.120 |
Why?
| | Solitary Pulmonary Nodule | 1 | 2015 | 21 | 0.120 |
Why?
| | Tumor Microenvironment | 1 | 2020 | 668 | 0.120 |
Why?
| | Phantoms, Imaging | 1 | 2016 | 145 | 0.120 |
Why?
| | Pattern Recognition, Automated | 1 | 2015 | 72 | 0.120 |
Why?
| | Societies, Medical | 1 | 2019 | 818 | 0.110 |
Why?
| | Antibodies, Antinuclear | 1 | 2015 | 69 | 0.110 |
Why?
| | Heart Block | 1 | 2015 | 41 | 0.110 |
Why?
| | Sjogren's Syndrome | 1 | 2015 | 52 | 0.110 |
Why?
| | Microcomputers | 1 | 2014 | 17 | 0.110 |
Why?
| | Software Design | 1 | 2014 | 25 | 0.110 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 821 | 0.110 |
Why?
| | Aged | 5 | 2024 | 23938 | 0.100 |
Why?
| | Stents | 1 | 2018 | 523 | 0.100 |
Why?
| | United States | 3 | 2016 | 14925 | 0.100 |
Why?
| | Biopsy | 1 | 2017 | 1089 | 0.100 |
Why?
| | Hemorrhage | 1 | 2018 | 719 | 0.100 |
Why?
| | Information Storage and Retrieval | 1 | 2014 | 117 | 0.100 |
Why?
| | Patient Satisfaction | 1 | 2017 | 677 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2016 | 2022 | 0.090 |
Why?
| | Diagnosis, Differential | 1 | 2016 | 1488 | 0.090 |
Why?
| | Pregnancy Complications | 1 | 2015 | 528 | 0.080 |
Why?
| | Adult | 5 | 2019 | 37910 | 0.080 |
Why?
| | Disease Models, Animal | 1 | 2020 | 4301 | 0.080 |
Why?
| | Electronic Health Records | 1 | 2017 | 1073 | 0.080 |
Why?
| | Prevalence | 1 | 2016 | 2735 | 0.080 |
Why?
| | Anthropometry | 1 | 2024 | 211 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2015 | 2525 | 0.050 |
Why?
| | Adipose Tissue | 1 | 2024 | 643 | 0.040 |
Why?
| | Survival Rate | 1 | 2024 | 1906 | 0.040 |
Why?
| | Mice, Nude | 1 | 2020 | 688 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2020 | 945 | 0.030 |
Why?
| | Plastics | 1 | 2018 | 50 | 0.030 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 206 | 0.030 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 190 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2020 | 1260 | 0.030 |
Why?
| | Metals | 1 | 2018 | 139 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2020 | 864 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2019 | 7609 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2011 | 10813 | 0.030 |
Why?
| | Prognosis | 1 | 2024 | 3966 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1706 | 0.030 |
Why?
| | Immunotherapy | 1 | 2020 | 628 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2024 | 5121 | 0.030 |
Why?
| | Fetal Diseases | 1 | 2015 | 173 | 0.030 |
Why?
| | Ultrasonography, Prenatal | 1 | 2015 | 285 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2020 | 2467 | 0.020 |
Why?
| | Incidence | 1 | 2018 | 2805 | 0.020 |
Why?
| | Apoptosis | 1 | 2020 | 2551 | 0.020 |
Why?
| | Infant | 1 | 2018 | 9539 | 0.010 |
Why?
| | Child, Preschool | 1 | 2018 | 11102 | 0.010 |
Why?
| | Mice | 1 | 2020 | 17748 | 0.010 |
Why?
| | Pregnancy | 1 | 2015 | 6770 | 0.010 |
Why?
| | Young Adult | 1 | 2018 | 13203 | 0.010 |
Why?
| | Adolescent | 1 | 2018 | 21435 | 0.010 |
Why?
| | Child | 1 | 2018 | 21833 | 0.010 |
Why?
| | Animals | 1 | 2020 | 37088 | 0.010 |
Why?
|
|
Clark's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|